Influencing factors for the functional cure of chronic hepatitis B and related mechanism

Yifei GUO; Jiming ZHANG

doi:10.3969/j.issn.1001-5256.2022.08.004

Volume 38 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(8): 1721-1725

PDF( 1897 KB)

Influencing factors for the functional cure of chronic hepatitis B and related mechanism

DOI: 10.3969/j.issn.1001-5256.2022.08.004

Yifei GUO¹,
Jiming ZHANG^{1, 2
,
,
,}

1.
National Medical Center for Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China
2.
Shanghai Institute of Major Infectious Diseases and Biosafety, Shanghai 200032, China

More Information

Corresponding author: ZHANG Jiming, jmzhang@fudan.edu.cn(ORCID: 0000-0001-5820-950X)
Received Date: 2022-06-30
Accepted Date: 2022-07-31
Published Date: 2022-08-20

Abstract

Abstract

Functional cure of chronic hepatitis B (CHB), defined as negative hepatitis B surface antigen (HBsAg) with or without the presence of hepatitis B surface antibody (anti-HBs), is considered the optimal endpoint for CHB treatment at present. Studies have shown that HBsAg clearance can reduce the risk of HBV complications such as liver cirrhosis and hepatocellular carcinoma. However, HBsAg clearance rate remains at a relatively low level, which may be associated with the immune tolerance state caused by HBV infection. HBsAg clearance and/or the presence of anti-HBs indicate the partial recovery of HBV-specific immunity. This article discusses the influencing factors for the functional cure of CHB and the underlying mechanisms.
- Hepatitis B, Chronic,
- Hepatitis B Surface Antigens,
- Hepatitis B e Antigens,
- Antiviral Agents

FullText(HTML)

References(48)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	YIP TC, WONG GL, CHAN HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014.
[3]	SIMONETTI J, BULKOW L, MCMAHON BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus[J]. Hepatology, 2010, 51(5): 1531-1537. DOI: 10.1002/hep.23464.
[4]	ZHOU K, CONTAG C, WHITAKER E, et al. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses[J]. Lancet Gastroenterol Hepatol, 2019, 4(3): 227-238. DOI: 10.1016/S2468-1253(18)30308-X.
[5]	CAO Z, LIU Y, MA L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4): 1058-1066. DOI: 10.1002/hep.29213.
[6]	SONNEVELD MJ, CHIU SM, PARK JY, et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels[J]. J Hepatol, 2022, 76(5): 1042-1050. DOI: 10.1016/j.jhep.2022.01.007.
[7]	HIRODE G, CHOI H, CHEN CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B Study)[J]. Gastroenterology, 2022, 162(3): 757-771. e4. DOI: 10.1053/j.gastro.2021.11.002.
[8]	PFEFFERKORN M, SCHOTT T, BÖHM S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2021, 74(2): 283-292. DOI: 10.1016/j.jhep.2020.08.039.
[9]	TIAN Y, KUO CF, AKBARI O, et al. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission[J]. Immunity, 2016, 44(5): 1204-1214. DOI: 10.1016/j.immuni.2016.04.008.
[10]	FUNG J, WONG DK, SETO WK, et al. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis[J]. Am J Gastroenterol, 2014, 109(11): 1764-1770. DOI: 10.1038/ajg.2014.301.
[11]	WONG D, LITTLEJOHN M, YUEN L, et al. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients[J]. Aliment Pharmacol Ther, 2018, 47(1): 114-122. DOI: 10.1111/apt.14362.
[12]	HOU FQ, SONG LW, YUAN Q, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon[J]. Theranostics, 2015, 5(3): 218-226. DOI: 10.7150/thno.10636.
[13]	BRAKENHOFF SM, de KNEGT RJ, OLIVEIRA J, et al. Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients[J]. J Infect Dis, 2022. DOI: 10.1093/infdis/jiac210.[Online ahead of print]
[14]	TESTONI B, LEBOSSÉ F, SCHOLTES C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4): 615-625. DOI: 10.1016/j.jhep.2018.11.030.
[15]	LIU J, YANG HI, LEE MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study[J]. Gastroenterology, 2010, 139(2): 474-482. DOI: 10.1053/j.gastro.2010.04.048.
[16]	VELKOV S, OTT JJ, PROTZER U, et al. The global hepatitis B virus genotype distribution approximated from available genotyping data[J]. Genes (Basel), 2018, 9(10): 495. DOI: 10.3390/genes9100495.
[17]	TSENG TC, LIU CJ, CHEN CL, et al. Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection[J]. Aliment Pharmacol Ther, 2015, 41(10): 949-960. DOI: 10.1111/apt.13170.
[18]	HEATHCOTE EJ, MARCELLIN P, BUTI M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology, 2011, 140(1): 132-143. DOI: 10.1053/j.gastro.2010.10.011.
[19]	JANSSEN HL, VAN ZONNEVELD M, SENTURK H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial[J]. Lancet, 2005, 365(9454): 123-129. DOI: 10.1016/S0140-6736(05)17701-0.
[20]	TERRAULT NA, WAHED AS, FELD JJ, et al. Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort[J]. Hepatology, 2022, 75(3): 709-723. DOI: 10.1002/hep.32231.
[21]	WANG L, ZHAO J, LIU J, et al. Long-term benefits of interferon-α therapy in children with HBeAg-positive immune-active chronic hepatitis B[J]. J Viral Hepat, 2021, 28(11): 1554-1562. DOI: 10.1111/jvh.13598.
[22]	YAO N, WANG J, WU Y, et al. Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: An opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B[J]. J Viral Hepat, 2022. DOI: 10.1111/jvh.13720. [Online ahead of print]
[23]	HUANG J, ZHANG K, CHEN W, et al. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs[J]. Sci Rep, 2017, 7(1): 13383. DOI: 10.1038/s41598-017-13747-9.
[24]	BOURLIÈRE M, RABIEGA P, GANNE-CARRIE N, et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 177-188. DOI: 10.1016/S2468-1253(16)30189-3.
[25]	QIU K, LIU B, LI SY, et al. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance[J]. Aliment Pharmacol Ther, 2018, 47(10): 1340-1348. DOI: 10.1111/apt.14629.
[26]	THIMME R, WIELAND S, STEIGER C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection[J]. J Virol, 2003, 77(1): 68-76. DOI: 10.1128/jvi.77.1.68-76.2003.
[27]	PARK JJ, WONG DK, WAHED AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B[J]. Gastroenterology, 2016, 150(3): 684-695. e5. DOI: 10.1053/j.gastro.2015.11.050.
[28]	XIONG S, ZHU D, LIANG B, et al. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss[J]. EBioMedicine, 2021, 69: 103464. DOI: 10.1016/j.ebiom.2021.103464.
[29]	KIM JH, GHOSH A, AYITHAN N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients[J]. Sci Rep, 2020, 10(1): 1835. DOI: 10.1038/s41598-020-58870-2.
[30]	ALIABADI E, URBANEK-QUAING M, MAASOUMY B, et al. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection[J]. Gut, 2021. DOI: 10.1136/gutjnl-2021-324646. [Online ahead of print]
[31]	LE BERT N, GILL US, HONG M, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection[J]. Gastroenterology, 2020, 159(2): 652-664. DOI: 10.1053/j.gastro.2020.04.019.
[32]	HOOGEVEEN RC, DIJKSTRA S, BARTSCH LM, et al. Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen+ infection[J]. J Hepatol, 2022. DOI: 10.1016/j.jhep.2022.05.041. [Online ahead of print]
[33]	SETO WK, CHAN TS, HWANG YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study[J]. J Clin Oncol, 2014, 32(33): 3736-3743. DOI: 10.1200/JCO.2014.56.7081.
[34]	LE BERT N, SALIMZADEH L, GILL US, et al. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(1): 34-44. DOI: 10.1016/j.jhep.2019.07.015.
[35]	BURTON AR, PALLETT LJ, MCCOY LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest, 2018, 128(10): 4588-4603. DOI: 10.1172/JCI121960.
[36]	SALIMZADEH L, LE BERT N, DUTERTRE CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest, 2018, 128(10): 4573-4587. DOI: 10.1172/JCI121957.
[37]	XU H, LOCARNINI S, WONG D, et al. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A[J]. J Hepatol, 2022, 76(1): 34-45. DOI: 10.1016/j.jhep.2021.07.031.
[38]	DUNN C, PEPPA D, KHANNA P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection[J]. Gastroenterology, 2009, 137(4): 1289-1300. DOI: 10.1053/j.gastro.2009.06.054.
[39]	YANG F, YU X, ZHOU C, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection[J]. PLoS Pathog, 2019, 15(4): e1007690. DOI: 10.1371/journal.ppat.1007690.
[40]	VISVANATHAN K, SKINNER NA, THOMPSON AJ, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein[J]. Hepatology, 2007, 45(1): 102-110. DOI: 10.1002/hep.21482.
[41]	MITRA B, WANG J, KIM ES, et al. Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation[J]. J Virol, 2019, 93(13): e00196-19. DOI: 10.1128/JVI.00196-19.
[42]	OP DEN BROUW ML, BINDA RS, van ROOSMALEN MH, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus[J]. Immunology, 2009, 126(2): 280-289. DOI: 10.1111/j.1365-2567.2008.02896.x.
[43]	BJÖRKSTRÖM NK, STRUNZ B, LJUNGGREN HG. Natural killer cells in antiviral immunity[J]. Nat Rev Immunol, 2022, 22(2): 112-123. DOI: 10.1038/s41577-021-00558-3.
[44]	NISHIO A, BOLTE FJ, TAKEDA K, et al. Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection[J]. Sci Transl Med, 2021, 13(587): eaba6322. DOI: 10.1126/scitranslmed.aba6322.
[45]	FANG Z, ZHANG Y, ZHU Z, et al. Monocytic MDSCs homing to thymus contribute to age-related CD8⁺ T cell tolerance of HBV[J]. J Exp Med, 2022, 219(4): e20211838. DOI: 10.1084/jem.20211838.
[46]	WANG H, LUO H, WAN X, et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection[J]. J Hepatol, 2020, 72(1): 45-56. DOI: 10.1016/j.jhep.2019.08.024.
[47]	LUCIFORA J, XIA Y, REISINGER F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176): 1221-1228. DOI: 10.1126/science.1243462.
[48]	TAN AT, HOANG LT, CHIN D, et al. Reduction of HBV replication prolongs the early immunological response to IFNα therapy[J]. J Hepatol, 2014, 60(1): 54-61. DOI: 10.1016/j.jhep.2013.08.020.

Relative Articles

[1]	Jinqiu YANG, Wenxia ZHAO, Cheng ZHOU, Tong LIU. Risk factors for the development of advanced liver fibrosis in nonalcoholic fatty liver disease and establishment of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(8): 1579-1584. doi: 10.12449/JCH240812
[2]	Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
[3]	Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
[4]	Mingqiang ZHU, Dashuai YANG, Junpeng PEI, Xiangyun XIONG, Yang SU, Youming DING. Analysis of influencing factors on biliary complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2023, 39(7): 1627-1632. doi: 10.3969/j.issn.1001-5256.2023.07.017
[5]	Sufang LU, Rui HUANG, Hongli ZHAO, Dandan WANG, Yuzhen DING, Hong ZHOU. Value of a risk assessment model in predicting venous thromboembolism in patients with liver failure after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 613-619. doi: 10.3969/j.issn.1001-5256.2023.03.019
[6]	Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
[7]	Perioperative Management Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Expert consensus on perioperative vascular complications for liver transplantation(2021)[J]. Journal of Clinical Hepatology, 2021, 37(9): 2054-2057. doi: 10.3969/j.issn.1001-5256.2021.09.010
[8]	Bing GUO, Mingquan PANG, Xiaolei XU, Junwei HAN, Haijiu WANG. Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2626-2631. doi: 10.3969/j.issn.1001-5256.2021.11.027
[9]	Yun ZHAO, Lijin ZHAO. Research advances in the risk factors for infection after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(8): 1957-1962. doi: 10.3969/j.issn.1001-5256.2021.08.046
[10]	Mingwei LI, Jian GAO, Xiangwei ZHAI, Xiangjun QIAN, Xiajie WEN, Mingjie YAO, Zhaojun DUAN, Erjiang ZHAO, Ling ZHANG, Fengmin LU. Construction and analysis of a predictive model for posthepatectomy recurrence in patients with hepatocellular carcinoma based on preoperative CXCL13 measurement[J]. Journal of Clinical Hepatology, 2021, 37(4): 823-828. doi: 10.3969/j.issn.1001-5256.2021.04.020
[11]	Wang Han, Zuo XiangRong, Cao Quan. Predictive factors and interventions for prolonged mechanical ventilation after liver transplantation[J]. Journal of Clinical Hepatology, 2020, 36(7): 1658-1662. doi: 10.3969/j.issn.1001-5256.2020.07.047
[12]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[13]	Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
[14]	Chen Long, Li Yue. The risk factors and prediction systems for posthepatectomy complications[J]. Journal of Clinical Hepatology, 2019, 35(1): 217-221. doi: 10.3969/j.issn.1001-5256.2019.01.048
[15]	Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
[16]	Zhang YinTao, Meng JinYing, Guo ChunGuang, Wang Hua. Risk factors for biliary complications after common bile duct exploration combined with primary suture[J]. Journal of Clinical Hepatology, 2017, 33(2): 304-307. doi: 10.3969/j.issn.1001-5256.2017.02.021
[17]	Wang XinWei, Zhao ZongGang. Risk factors for infectious complications after hepatectomy in patients with intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(9): 1754-1757. doi: 10.3969/j.issn.1001-5256.2017.09.025
[18]	Wang MingYue, Lu ZhiYan. Imaging evaluation of complications after liver transplantation[J]. Journal of Clinical Hepatology, 2016, 32(12): 2295-2299. doi: 10.3969/j.issn.1001-5256.2016.12.013
[19]	Lu: GuoYue. Risk factors for biliary complications after liver transplantation from donation after cardiac death[J]. Journal of Clinical Hepatology, 2015, 31(12): 2027-2030. doi: 10.3969/j.issn.1001-5256.2015.12.009
[20]	Chen Man, Zhang Xia. Research advances in molecular prediction of recurrence and metastasis of primary liver cancer after liver transplantation[J]. Journal of Clinical Hepatology, 2014, 30(12): 1361-1365. doi: 10.3969/j.issn.1001-5256.2014.12.032

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	李正优，李荷，周俊. 预见性护理结合舒适护理干预在肝移植术后患者中的应用. 西藏医药. 2024(06): 123-125 .
2.	李珊珊，王媛，高春辉. 早期下床活动对肝移植术后患者胃肠功能及下肢血流的影响. 国际移植与血液净化杂志. 2023(01): 41-44 .
3.	张欣悦，王海刚，王昊，杨传伟. 他克莫司治疗1例肝移植术后患者的药学监护. 中国医药导报. 2023(14): 183-187 .
4.	种庚，彭晓春，吴若林，赵红川，邵敏. 成人肝移植术后早期严重并发症相关危险因素分析. 肝胆外科杂志. 2022(06): 454-459 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (970) PDF downloads(271)

Influencing factors for the functional cure of chronic hepatitis B and related mechanism

DOI: 10.3969/j.issn.1001-5256.2022.08.004